Comparison Between 2D and 3D Dosimetry Protocols in 90Y-Ibritumomab Tiuxetan Radioimmunotherapy of Patients with Non-Hodgkin's Lymphoma-Reference-Cited by-同舟云学术

Comparison Between 2D and 3D Dosimetry Protocols in 90Y-Ibritumomab Tiuxetan Radioimmunotherapy of Patients with Non-Hodgkin's Lymphoma

Published:2008-02 Issue:1 Volume:23 Page:53-64
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Assié Karine¹²,Dieudonné Arnaud¹,Gardin Isabelle¹³,Buvat Irène²,Tilly Hervé⁴,Vera Pierre¹³

Affiliation:

1. Laboratoire LITIS (EA 4108), Université de Rouen, Rouen, France

2. Unité 678 INSERM – Université Pierre et Marie Curie, Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France

3. Département de Médecine Nucléaire, Centre Hospitalier Universitaire, Centre Henri Becquerel, Rouen, France

4. Département d' Hématologie et Groupe d' Etude des Proliférations Lymphoïdes, INSERM U614, IFR23, Centre Henri Becquerel, Rouen, France

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/cbr.2007.372

Reference32 articles.

1. Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

2. Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An update;Seminars in Nuclear Medicine;2023-05

2. Dosimetric Approaches for Radioimmunotherapy of Non-Hodgkin Lymphoma in Myeloablative Setting;Seminars in Nuclear Medicine;2022-03

3. Resistance and Heterogeneity of Intratumoral Antibody Distribution;Resistance to Targeted Anti-Cancer Therapeutics;2018

4. Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody–Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan;Journal of Nuclear Medicine;2017-08-28

5. Metal Complexes for Detecting Disease;Metals in Medicine;2017-05-06